129 related articles for article (PubMed ID: 38849758)
21. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.
Yang P; Ren Y; Li B; Fang W; Meng Q; Kijlstra A
Ophthalmology; 2007 Mar; 114(3):606-14. PubMed ID: 17123618
[TBL] [Abstract][Full Text] [Related]
23. Quantitative evaluation of "sunset glow" fundus in Vogt-Koyanagi-Harada disease.
Suzuki S
Jpn J Ophthalmol; 1999; 43(4):327-33. PubMed ID: 10482481
[TBL] [Abstract][Full Text] [Related]
24. Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease.
Kaya P; İnanç Tekin M; Özdal PÇ
Ocul Immunol Inflamm; 2023 Oct; 31(8):1687-1693. PubMed ID: 36628436
[TBL] [Abstract][Full Text] [Related]
25. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
26. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease.
Rao NA; Gupta A; Dustin L; Chee SP; Okada AA; Khairallah M; Bodaghi B; Lehoang P; Accorinti M; Mochizuki M; Prabriputaloong T; Read RW
Ophthalmology; 2010 Mar; 117(3):591-9, 599.e1. PubMed ID: 20036008
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Value of Optical Coherence Tomography in the Early Diagnosis of Macular Complications in Chronic Vogt-Koyanagi-Harada Disease.
Agarwal M; Radosavljevic A; Patnaik G; Rishi E; Pichi F
Ocul Immunol Inflamm; 2022 May; 30(4):801-808. PubMed ID: 33136534
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
Takayama K; Obata H; Takeuchi M
Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
[No Abstract] [Full Text] [Related]
29. Vogt Koyanagi Harada Disease In Paediatric Age Group: Clinical Characteristics, Remission, Recurrences and Complications in Asian Indian Population.
Kaza H; Tyagi M; Agarwal K; Behera S; Pappuru RR; Mohan S; Saldanha M; Videkar C; Basu S; Pathengay A; Murthy S
Semin Ophthalmol; 2022 Feb; 37(2):187-192. PubMed ID: 34224303
[TBL] [Abstract][Full Text] [Related]
30. Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset.
Ei Ei Lin Oo ; Chee SP; Wong KKY; Hla Myint Htoon
Am J Ophthalmol; 2020 Dec; 220():37-44. PubMed ID: 32738228
[TBL] [Abstract][Full Text] [Related]
31. Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.
Zhang C; Wang Y; Chen Y; Zhou H; Hong Q; Yu X; Ng TK; Cen LP
BMC Ophthalmol; 2023 May; 23(1):199. PubMed ID: 37147563
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome.
Jeroudi A; Angeles-Han ST; Yeh S
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(4):332-4. PubMed ID: 25037015
[TBL] [Abstract][Full Text] [Related]
33. Ocular Inflammation and Choroidal Thickness after Pars Plana Vitrectomy in Chronic Recurrent Stage of Vogt-Koyanagi-Harada Disease.
Park UC; Yu HG
Ocul Immunol Inflamm; 2021 Feb; 29(2):388-395. PubMed ID: 31671005
[No Abstract] [Full Text] [Related]
34. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.
Muto T; Sakamoto M; Imaizumi S; Kamoi K
J Int Med Res; 2024 Jan; 52(1):3000605231221081. PubMed ID: 38170955
[TBL] [Abstract][Full Text] [Related]
35. Vogt-Koyanagi-Harada disease in Hispanic patients.
Sukavatcharin S; Tsai JH; Rao NA
Int Ophthalmol; 2007; 27(2-3):143-8. PubMed ID: 17380271
[TBL] [Abstract][Full Text] [Related]
36. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey.
Tugal-Tutkun I; Ozyazgan Y; Akova YA; Sullu Y; Akyol N; Soylu M; Kazokoglu H
Int Ophthalmol; 2007; 27(2-3):117-23. PubMed ID: 16957877
[TBL] [Abstract][Full Text] [Related]
37. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi-Harada disease: Prevention of late autoimmune complications by early intervention.
Abu El-Asrar AM; Al Rashed FA; AlBloushi AF; Tobaigy MF; Gikandi PW; Herbort CP; Opdenakker G
Acta Ophthalmol; 2023 Mar; 101(2):e236-e245. PubMed ID: 36128841
[TBL] [Abstract][Full Text] [Related]
39. Vogt-Koyanagi-Harada disease.
O'Keefe GA; Rao NA
Surv Ophthalmol; 2017; 62(1):1-25. PubMed ID: 27241814
[TBL] [Abstract][Full Text] [Related]
40. Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area.
Herbort CP; Tugal-Tutkun I; Khairallah M; Abu El Asrar AM; Pavésio CE; Soheilian M
Int Ophthalmol; 2020 Sep; 40(9):2423-2433. PubMed ID: 32418076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
